市場調查報告書
商品編碼
1249921
全球體外診斷市場:按產品、按測試、按應用、按最終用戶和預測,2023-2032 年In-vitro Diagnostics Market - By Product, By Test, By Application, By End-user & Forecast, 2023 - 2032 |
由於醫療保健基礎設施的持續改進以及政府和私人病理實驗室的增加,體外診斷市場預計將從 2023 年到 2032 年顯著增長。
此外,增加政府舉措(例如資助診斷中心和支持開發更新、技術更先進的體外診斷設備)預計將在預計期間促進行業擴張。
總體而言,體外診斷行業按產品、測試、應用、最終用途和地理位置進行細分。
由於診斷設備在醫療保健領域的應用不斷擴大,設備領域有望在 2032 年大幅增長。 診斷測試廣泛用於檢測多種疾病和進行常規健康檢查。 此外,快速擴張的醫療保健市場和醫療保健投資的激增預計也將促進這一領域的增長。 順便說一句,美國的醫療保健支出將在 2021 年增長 2.7%,達到 4.3 萬億美元的驚人規模。
從考試領域來看,臨床化學領域預計從 2023 年到 2032 年將呈現顯著增長。 在藥物發現開發中越來越多地使用臨床化學正在推動該行業的擴張。 體外診斷自動化的引入也有望對該領域的增長產生積極影響。
根據應用,到 2032 年,糖尿病行業的價值預計將超過 210 億美元。 預計在糖尿病預防和管理方面的努力和資金的增加將推動體外診斷市場。 糖尿病的早期診斷和檢測使該疾病更易於管理並改善患者預後。
按最終用途劃分,預計學術和研究機構在預測期內的複合年增長率將超過 2.5%。 體外診斷 (IVD) 在學術和研究機構中極為重要,因為它們允許科學家和研究人員在受控環境中研究和分析生物樣本。 此外,越來越多的研發項目以及學術和研究機構越來越多地使用分子診斷來分析藥物安全性和敏感性,將進一步推動該領域的發展。
按地區劃分,到 2032 年,歐洲體外診斷市場估計將超過 320 億美元。 公共機構和私營公司增加的床旁分子診斷教育活動正在促進該地區的市場增長。 此外,預計醫療診斷設備的技術創新將進一步推動市場增長。
In-vitro Diagnostics Market is anticipated to grow significantly from 2023 to 2032, owing to the constant improvements in the healthcare infrastructure and the increasing number of government and privately owned pathology labs. Besides, growing initiatives taken by the governments, such as funding diagnostic centers and supporting the development of newer, technologically advanced in-vitro devices, are expected to favor industry expansion during the estimated timeframe.
Overall, the in-vitro diagnostics industry is segmented in terms of product, test, application, end-use, and region.
Based on product, the instruments segment will grow exponentially during 2032 owing to the increasing application of diagnostic instruments in the healthcare sector. Diagnostic testing is widely used to detect several conditions and for routine health checkups. Moreover, the rapidly expanding healthcare market and constantly surging investments in healthcare will further contribute to segmental growth. For the record, the US health spending increased by 2.7% in 2021, reaching a whopping USD 4.3 trillion.
By test, the clinical chemistry segment will showcase considerable growth during 2023-2032. The mounting use of clinical chemistry in drug discovery and development will support the industry expansion. In addition, introduction to automation in the in-vitro diagnostic devices will also positively influence segmental growth.
Considering the application, the diabetes segment is anticipated to be valued at over USD 21 billion by 2032. Increasing initiatives and funding for diabetes prevention and management will drive the in-vitro diagnostics market. Early diagnosis and detection of diabetes can result in managing the disease better and offer enhanced patient outcomes.
In terms of end-use, the academic & research institutes segment will exhibit over 2.5% CAGR during the forecast time. In vitro diagnostics (IVD) is crucial in academic and research institutes as it empowers scientists and researchers to study and analyze biological samples in a controlled environment. Besides, the increasing number of research and development projects, along with the budding use of molecular diagnostics in analyzing drug safety and sensitivity in academic and research institutes, will further augment segmental growth.
Regionally, the Europe in-vitro diagnostics market is estimated to be valued at over USD 32 billion by 2032. Increasing efforts made by public and private organizations to spread awareness regarding point-of-care molecular diagnostics will contribute to the regional market growth. Besides, the rising technological innovations across medical diagnostic devices will further boost market growth.